From Th1 to Th2: Diabetes immunotherapy shifts gears
- 1 December 1996
- journal article
- Published by Springer Nature in Nature Medicine
- Vol. 2 (12) , 1311-1312
- https://doi.org/10.1038/nm1296-1311
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes–prone miceNature Medicine, 1996
- Recurrence of Autoimmune Diabetes Mellitus in Recipients of Cadaveric Pancreatic GraftsNew England Journal of Medicine, 1996
- Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes.The Journal of Experimental Medicine, 1996
- CD8 T cell clones from young nonobese diabetic (NOD) islets can transfer rapid onset of diabetes in NOD mice in the absence of CD4 cells.The Journal of Experimental Medicine, 1996
- Prevention of Autoimmune Diabetes in Nonobese Diabetic Female Mice by Treatment with Recombinant Glutamic Acid Decarboxylase (GAD 65)Clinical Immunology and Immunopathology, 1995
- Peptide therapy for diabetes in NOD miceThe Lancet, 1994
- Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic miceNature, 1993
- Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetesNature, 1993
- Insulin prophylaxis in individuals at high risk of type 1 diabetesThe Lancet, 1993
- Autoimmunity to glutamic acid decarboxylase (GAD) in stiffman syndrome and insulin-dependent diabetes mellitusTrends in Neurosciences, 1991